Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuning Le

Showing results (121-130 of 179) with videos related to

Pageof 18
Sort By:
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.
Cancers|May 14, 2025
Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil ModelHui Li, Morteza Salehjahromi, Myrna C B Godoy, et al.
JTO Clinical and Research Reports|March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNASimon Heeke, Saumil Gandhi, Hai T Tran, et al.
JCO Precision Oncology|January 30, 2023
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals <i>EGFR</i> Mutations to Be Associated With Longer Overall SurvivalBrian De, Ahsan S Farooqi, Kyle G Mitchell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resectionXiuning Le, Frederico O Gleber-Netto, M Laura Rubin, et al.
Cancer Innovation|July 1, 2024
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomesSahil Seth, Runzhe Chen, Yang Liu, et al.
Oncogene|December 14, 2019
Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
Oncogene|November 23, 2019
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
JTO Clinical and Research Reports|August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLCKaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Pageof 18

Showing results (121-130 of 179) with videos related to

Sort By:
Pageof 18
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.
Cancers|May 14, 2025
Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil ModelHui Li, Morteza Salehjahromi, Myrna C B Godoy, et al.
JTO Clinical and Research Reports|March 31, 2025
Longitudinal Tracking of <i>ALK</i>-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNASimon Heeke, Saumil Gandhi, Hai T Tran, et al.
JCO Precision Oncology|January 30, 2023
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals <i>EGFR</i> Mutations to Be Associated With Longer Overall SurvivalBrian De, Ahsan S Farooqi, Kyle G Mitchell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resectionXiuning Le, Frederico O Gleber-Netto, M Laura Rubin, et al.
Cancer Innovation|July 1, 2024
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomesSahil Seth, Runzhe Chen, Yang Liu, et al.
Oncogene|December 14, 2019
Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
Oncogene|November 23, 2019
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutationYing Jin, Hua Bao, Xiuning Le, et al.
JTO Clinical and Research Reports|August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLCKaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.
Nature Communications|September 24, 2025
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivityXiuning Le, Jacqulyne P Robichaux, Monique Nilsson, et al.
Pageof 18